Published Date: August, 2017
Figure : Global Cardiovascular Implants Market by projection
Cardiovascular Disease (CVD) is generally refers to conditions affecting the heart or blood vessels. It’s usually associated with a build-up of fatty deposits inside the arteries – known as atherosclerosis, narrowing or blockage of blood vessels and an increased risk of blood clots. It can also be associated with damage to arteries in organs such as the brain, heart, kidneys and eyes. CVD is one of the main causes of death and disability in the UK, but it can often largely be prevented with a healthy lifestyle. These cardiovascular diseases generally triggered by various factors such as life style, heart rhythm complications, smoking, high cholesterol, lack of exercise, diabetes, obesity, poor diet, alcohol consumption and high blood pressure. Among these factors, high blood pressure results in 13% of CVD deaths, while tobacco results in 9%, diabetes 6%, lack of exercise 6% and obesity 5%.
CVDs includes coronary artery diseases (CAD) such as angina and myocardial infarction (heart attack). Other CVDs are peripheral arterial disease, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis. There various treatment options available in the market to treat these cardiovascular diseases such as drug therapy (ACE inhibitors, antiarrhythmic, aspirin therapy, beta-blocker therapy, clot buster drugs, diuretics, etc.), changing lifestyle habits, and medical surgeries (stents, coronary stents, peripheral stents, heart bypass surgery, pacemakers, implantable cardioverter defibrillators, and heart transplants). These implants are lifesaving medium to improve the patient’s disease condition and are made of various materials, which includes metals, alloys, biomaterials, and polymers.
Some of the key driving factors attributing to the growth of this include increasing number of patients with cardiovascular diseases such as hypertension, heart failures and coronary artery diseases, and shortage of number of heart donors. In addition, changing lifestyle, alcohol consumption, growing obesity and smoking further propelling the market growth, as these factors increase the bold glucose and lipid levels, which results in serious cardiovascular diseases. According to American Heart Association publication, it has been estimated that in the US alone approximately 5.5 million people suffered from heart failure in 2013 and 300,000 die each year because of heart failure. The market for global cardiovascular implants was valued at USD 26.1 billion in 2015 and is expected to reach around USD 39.0 billion by 2022, growing at a CAGR of 5.8% during the forecast period of 2016 to 2022. However, there are certain restraining factors which could hamper the growth of the market, which includes, high-risk nature and high complication rates associated with considerable mortality, due to frequent use of implants in older populations with frequent co-morbidities. Geographically, North America is leading contributor to the market and is expected to retain its position during the forecast period. Nonetheless, the market for Asia-Pacific region is expected to grow at a faster rate owing to increasing prevalence of CVD diseases, growing awareness among the population, improving healthcare infrastructure, rise in healthcare spending, and favorable government policies.
• Abbott Laboratories
• Boston Scientific
• Medtronic plc.
• St. Jude Medical, Inc.
• C. R. Bard, Inc.
• Cook Medical
• Terumo Corporation
• Edwards Lifesciences
• AMG International.
The report delivers a strategic analysis of the global market for cardiovascular implants and growth forecast for the period from 2016 – 2022. The scope of the report includes competitive analysis of various market players who are operating in the market, segmental analysis based on type of implants. It also covers geographical analysis of the market with growth forecast for the period of 2016 – 2022. The Porter’s Five Forces analysis and value chain analysis included in the report provides an insight into market dynamics and industry competition.
The study also provides information for recent merger and acquisition deals happened in the global cardiovascular implants market. Moreover, the report also includes growth strategies and entry barriers to be considered to cater to the exact business opportunities in this market. Additionally, to aid in strategic decision making, the report also includes competitive profiling of leading players, recent developments in the industry and various business strategies adopted by them. This report will help players in global cardiovascular implants market to plan and implement their strategies in different market areas such as emerging geographies, and new technologies.
1 Scope of the report
1.1 Report description
1.2 Research methodology
1.3 List of abbreviations
1.4 Market segmentation
2 Executive summary
3 Qualitative analysis
3.1 Market overview
3.2 Value chain analysis
3.3 Porters five forces analysis
3.4 Key M&A trends and strategic partnerships
3.5 Competitive matrix of the key companies
4 Global cardiovascular implants market, by type, 2015 – 2022
4.1 Coronary stents
4.2 Peripheral stents
4.3 Heart valves
4.4 Implanted cardiac pacemakers
4.5 Implantable Cardioverter Defibrillator (ICD)
4.6 Cardiac Resynchronization Therapy (CRT) device
5 Global cardiovascular implants market, by geography, 2015 – 2022
5.1 North America
5.1.1 Coronary stents
5.1.2 Peripheral stents
5.1.3 Heart valves
5.1.4 Implanted cardiac pacemakers
5.1.5 Implantable Cardioverter Defibrillator (ICD)
5.1.6 Cardiac Resynchronization Therapy (CRT) device
5.2.1 Coronary stents
5.2.3 Heart valves
5.2.4 Implanted cardiac pacemakers
5.2.5 Implantable Cardioverter Defibrillator (ICD)
5.2.6 Cardiac Resynchronization Therapy (CRT) device
5.3.1 Coronary stents
5.3.2 Peripheral stents
5.3.3 Heart valves
5.3.4 Implanted cardiac pacemakers
5.3.5 Implantable Cardioverter Defibrillator (ICD)
5.3.6 Cardiac Resynchronization Therapy (CRT) device
5.4 Rest of the World
5.4.1 Coronary stents
5.4.2 Peripheral stents
5.4.3 Heart valves
5.4.4 Implanted cardiac pacemakers
5.4.5 Implantable Cardioverter Defibrillator (ICD)
5.4.6 Cardiac Resynchronization Therapy (CRT) device
6 Company profiles
6.1 Abbott Laboratories
6.3 Boston Scientific
6.4 Medtronic plc.
6.5 St. Jude Medical, Inc.,
6.6 C. R. Bard, Inc.
6.7 Cook Medical
6.8 Terumo Corporation
6.9 Edwards Lifesciences
6.10 AMG International